CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T CellsMatthias Braun, Tobias Bald, Amelia Roman Aguilera et al.|Immunity|2020Cited by 181
The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphomaKimberley Jones, Maher K. Gandhi, Leesa Wockner et al.|Clinical & Experimental Immunology|2015Cited by 45
Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 <sup>+</sup> T CellsMatthias Braun, Tobias Bald, Indrajit Das et al.|SSRN Electronic Journal|2019Cited by 3
The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLDMaher K. Gandhi, Thanh D. Hoang, J. Lynn Fink et al.|Queensland's institutional digital repository (The University of Queensland)|2017Cited by 2